SCHEMBL297054

SCHEMBL297054

O=C(/C=C/c1ccn(S(=O)(=O)c2ccc(-c3ccncc3)cc2)c1)NO

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 16/20 0.62
HDAC6 Q9UBN7 14/20 0.62
HDAC3 O15379 13/20 0.61
HDAC8 Q9BY41 12/20 0.61
HDAC2 Q92769 15/20 0.54
HDAC10 Q969S8 12/20 0.54
HDAC11 Q96DB2 12/20 0.54
HDAC9 Q9UKV0 12/20 0.54
HDAC4 P56524 12/20 0.54
HDAC7 Q8WUI4 11/20 0.54
HDAC5 Q9UQL6 11/20 0.54
KDM1A O60341 1/20 0.53
ABL1 P00519 1/20 0.46
EGFR P00533 1/20 0.46
ERBB2 P04626 1/20 0.46
INSR P06213 1/20 0.46
PDGFRB P09619 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL297055 1.00 HDAC1 (0.62) HDAC1HDAC6HDAC3HDAC8HDAC2
SCHEMBL297876 0.88 HDAC1 (0.48) HDAC1HDAC6HDAC3HDAC8HDAC2
SCHEMBL3141726 0.88 HDAC1 (0.65) HDAC1HDAC6HDAC3HDAC8HDAC2
SCHEMBL3141718 0.88 HDAC1 (0.65) HDAC1HDAC6HDAC3HDAC8HDAC2
SCHEMBL297877 0.88 HDAC1 (0.48) HDAC1HDAC6HDAC3HDAC8HDAC2
SCHEMBL296490 0.88 HDAC1 (0.65) HDAC1HDAC6HDAC3HDAC8HDAC2
SCHEMBL296489 0.88 HDAC1 (0.65) HDAC1HDAC6HDAC3HDAC8HDAC2
SCHEMBL296243 0.88 HDAC1 (0.52) HDAC1HDAC6HDAC3HDAC8HDAC2
SCHEMBL296244 0.88 HDAC1 (0.52) HDAC1HDAC6HDAC3HDAC8HDAC2
SCHEMBL3136518 0.86 HDAC1 (0.62) HDAC1HDAC6HDAC3HDAC8HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725528-B1 SULPHONYLPYRROLES AS HDAC INHIBITORS 4SC AG (DE) 2013-05-29 EP claimed
US-20130079347-A1 NOVEL SULFONYLPYRROLES ALTANA PHARMA AG (DE) 2013-03-28 US claimed
CN-1926103-B Sulfonyl pyrroles as HDAC inhibitors 4SC AG 2012-12-19 CN claimed
US-20110166140-A1 NOVEL SULPHONYLPYRROLES MAIER THOMAS 2011-07-07 US claimed
US-20100261761-A1 Novel Sulfonylpyrroles MAIER THOMAS 2010-10-14 US claimed
US-20100261721-A1 Novel Sulphonylpyrroles MAIER THOMAS 2010-10-14 US claimed
US-20070184979-A1 Novel sulfonylpyrroles ALTANA PHARMA AG (DE) 2007-08-09 US claimed
CN-1926103-A Sulfonyl pyrroles as HDAC inhibitors ALTANA PHARMA AG (DE) 2007-03-07 CN claimed
EP-1725528-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP claimed
WO-2005087724-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO claimed
WO-2019043176-A2 HDAC INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY 4SC AG (DE) 2019-03-07 WO disclosed
US-8969401-B2 Sulfonylpyrroles 4SC AG (DE) 2015-03-03 US disclosed
EP-1725528-B1 SULPHONYLPYRROLES AS HDAC INHIBITORS 4SC AG (DE) 2013-05-29 EP disclosed
EP-1928826-B1 SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS 4SC AG (DE) 2013-04-24 EP disclosed
US-20130079347-A1 NOVEL SULFONYLPYRROLES ALTANA PHARMA AG (DE) 2013-03-28 US disclosed
WO-2007039404-A1 NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES NYCOMED GMBH (DE) 2007-04-12 WO disclosed
WO-2007039403-A1 SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS NYCOMED GMBH (DE) 2007-04-12 WO disclosed
CN-1926103-A Sulfonyl pyrroles as HDAC inhibitors ALTANA PHARMA AG (DE) 2007-03-07 CN disclosed
EP-1725528-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP disclosed
WO-2005087724-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070184979-A1 Novel sulfonylpyrroles HDAC1, HDAC4, HDAC3 HDAC1 1/4885HDAC6 8/4885HDAC3 3/4885
US-20110166140-A1 NOVEL SULPHONYLPYRROLES HDAC1, HDAC3, HDAC2 HDAC1 1/4885HDAC6 7/4885HDAC3 2/4885
US-20100261761-A1 Novel Sulfonylpyrroles HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC6 7/4885HDAC3 1/4885
US-20100261721-A1 Novel Sulphonylpyrroles HDAC1, HDAC3, HDAC2 HDAC1 1/4885HDAC6 7/4885HDAC3 2/4885
US-20130079347-A1 NOVEL SULFONYLPYRROLES HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC6 7/4885HDAC3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.